6th Macrophage-Directed Therapies Summit 2024
Evvnt Promotion / evvnt
01.10.2024 - 03.10.2024 Hilton Boston Back Bay, 40 Dalton Street, 02115 Boston, Massachusetts, USA
Time: 7:30 AM - 5:45 PM
Temi della conferenza
Despite toxicity concerns for CD47 targets in 2023, the macrophage therapies space remains determined to drive revolutionary treatments for oncology, autoimmunity, inflammation, neurodegenerative disorders, and beyond. From pioneering the next generation of CAR-M therapies to unveiling novel targets, this field is on a mission to learn from the past and spearhead pipelines into clinical development.
Despite toxicity concerns for CD47 targets in 2023, the macrophage therapies space remains determined to drive revolutionary treatments for oncology, autoimmunity, inflammation, neurodegenerative disorders, and beyond. From pioneering the next generation of CAR-M therapies to unveiling novel targets, this field is on a mission to learn from the past and spearhead pipelines into clinical development.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Annotazioni
URL:
Brochure: https://go.evvnt.com/2422009-3?pid=4832
Speakers: Bindu Varghese | Senior Director, In Vivo CAR-M Therapies Lead | Carisma Therapeutics, Charles Garvin | Chief Executive Officer | Riptide Bioscience, and more
URL:
Brochure: https://go.evvnt.com/2422009-3?pid=4832
Speakers: Bindu Varghese | Senior Director, In Vivo CAR-M Therapies Lead | Carisma Therapeutics, Charles Garvin | Chief Executive Officer | Riptide Bioscience, and more
Informazioni ed Iscrizioni:
https://go.evvnt.com/2422009-2?pid=4832
Ms. Kelly Cassidy
Medicina General
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."
